236 Studies Now Enrolling
Menu
Search
Status
Medical Condition
- Show all (299)
- Addiction (4)
- Autoimmune Disorders (1)
- Blood Disorders (1)
- Cancer (27)
- COVID-19 (Coronavirus) (1)
- Ear, Nose and Throat (3)
- Endocrine & Metabolic Disease (1)
- Eye (1)
- Healthy Volunteers (42)
- Heart Disease (1)
- Infectious Disease (2)
- Neurological Disorders (165)
- Obesity (1)
- Obstetrics & Gynecology (3)
- Pediatrics (10)
- Psychiatric Disorders (31)
- Rehabilitation (1)
- Stroke (1)
- Transplant (2)
- Vascular Conditions (1)
Displaying 1 - 4 of 4
Condition: Skin Cancer / Melanoma
Investigator: Richard Carvajal, MD
Status: Closed
The purpose of this research study is to determine if high-dose versus standard-dose regimens of encorafenib and binimetinib are safe and have positive effects in people who have melanoma brain metastasis and also have been found by their doctor to have a mutated gene called BRAFV600. The time frame for the study is…
Condition: Neurological Disorders / Huntington's Disease
Investigator: Ashwini Rao, EdD, OTR
Status: Closed
Dance is a complex activity involving the integration of rhythm, spatial patterns, synchronization to external stimuli and whole-body coordination. While regular exercise is often recommended for people with Huntington's Disease (HD), there are no studies examining the use of dance to improve balance and mobility and positively affect the quality of…
Condition: Neurological Disorders / Huntington's Disease
Investigator: Karen Marder, MD, MPH
Status: Closed
The DIMENSION Study is evaluating the safety and effect on cognitive symptoms of an investigational oral drug in adults with early Huntington's disease. Cognitive symptoms may include difficulty paying attention or trouble thinking through steps of an activity or complex problems. Symptoms may also include difficulty planning, remembering, and staying…
Condition: Neurological Disorders / Huntington's Disease
Investigator: Karen Marder, MD, MPH
Status: Closed
The purpose of this research study is to find out whether a new investigational drug called SRX246, which might be useful to Huntington's Disease (HD) patients who sometimes feel irritable, angry, or even aggressive, is well tolerated and safe when it is given two times a day by mouth at doses as high as 160 mg. As part of this study, we will use a…